Category: Zacks Small Cap Research

1323334353642340 / 414 POSTS
By David Bautz, PhDTSX:ATE.VAntibe Therapeutics Inc. (TSX:ATE.V) is a Canadian biotechnology company developing treatments for pain, inflammation, and regenerative medicine. The company’s lead compound, ATB-346, is an improved non-steroidal anti-infl ...
By Anita Dushyanth, PhDNASDAQ:PULMPulmatrix (NASDAQ:PULM) management filed a Clinical Trial Application (CTA) in 2H 2017 in the EU to support a Phase 1/1b trial in healthy volunteers and asthmatics, which is anticipated to commence in 1H 2018.  The ...
NYSE:HEBWith the stock up 50% over the past 3 months, we believe HEB (NYSE:HEB) is starting to look like an attractive investment.  Since our prior report (November 14, 2017), Hemispherx has made some progress in their Ampligen product development cy ...
By David Bautz, PhDNASDAQ:VKTXBusiness UpdateViking Therapeutics, Inc. (NASDAQ:VKTX) is currently testing VK2809, the company’s thyroid hormone receptor beta (TRβ) agonist, in a Phase 2 clinical trial in patients with hypercholesterolemia and fatty l ...
OTC:GBTCSince its successful ICO (Initial Coin Offering) which closed September 2017, the recently re-branded SOCIAL, has completed its transformation from Nexus to a blockchain and cryptocurrency leader and is well on its way to executing its expans ...
By John Vandermosten, CFANASDAQ:LPCNOn January 10, 2018 the 19 member Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) voted 13 to 6 against the benefit / risk profile for Lipocine Incorporated’s (NASDAQ:LPCN) Tlando (Testosterone un ...
By Anita Dushyanth, PhDNASDAQ:VRAYOn January 8, 2018 VRAY (NASDAQ:VRAY) announced preliminary financial results for Q4 and fiscal year 2017.Management had guided for 2017 revenues in the $42 - $47 million range.  Commensurate with management’s guidan ...
By Brian Marckx, CFANASDAQ:CTSOQ4 / FY2017 Preannouncement: Product Revenue Crushes Prior Record, Jumping 20% QoQ...On Monday (Jan 8th) CytoSorbents (NASDAQ:CTSO) preannounced expected Q4 revenue of approximately $4.6M (i.e. between $4.5M and $4.7) i ...
In the spring of 2014, Robin Smith and Kate Blanchard launched a new venture, which they named Orig3n. They had spent the previous three years at Perkin Elmer after it acquired their last startup, Artus Labs (Smith’s third company). By th ...
OTC:AXIMSummary• With legislative approval for the legalized use of marijuana-based compounds for medical purposes in 29 states, we expect medical cannabinoid stocks to be a prominent investment theme in 2018. • During the fourth quarter of 2017, can ...
1323334353642340 / 414 POSTS